羟考酮缓释片在缓解晚期肺癌疼痛中的效果观察

目的]观察羟考酮缓释片在多西他赛二线治疗伴随疼痛的晚期肺癌患者的疗效及安全性。方法]对2007年2月—2011年7月收治的40例中、重度肿瘤疼痛者采用羟考酮缓释片止痛,同时予多西他赛75 mg/m2静脉滴注1 h,第1天,每3周重复。观察治疗前后疗效、不良反应及生活质量评分。结果]有效率27.5%,疾病控制率60%,中位生存期9.35个月,1年生存率37.5%。与治疗前比较,患者疼痛程度有较大的缓解,疼痛缓解率为97.5%,数字模拟评分法(NRS)评分明显降低,KPS评分明显升高,差异均具有统计学意义(P<0.05)。不良反应主要是血液学毒性和便秘,治疗后可以缓解。结论]羟考酮缓释片联合多西他赛治疗中重度疼痛的肺癌安全有效,能明显改善病人的生活质量。

Clinical observation of Oxycodone Controlled-release Tablets in docetaxel second-line treatment of advanced lung cancer

Objective] To evaluate the efficacy and safety of oxycodone controlled-release tablets in patients with advanced non-small cell lung cancer （ NSCLC ） who suffered from cancer pain and needed the treatment of docetaxel as second-line drug. Methods] Data from 40 patients with NSCLC who suf-fered from moderate and severe cancer pain and were treated with oxycodone controlled -release tablets and docetaxel 75mg/m2 on d1 every 3 weeks from Feb 2007 to July 2011.The analgesic effects, karnofsky per-formance status scales （ KPS） and adverse effects were observed . Results] A group of 40 patients were available for evaluation, of whom the response rate was 27.5%,the disease control rate 60%,and the medi-an survival of all 9.35 months, with one-year survival rate being 37.5%.Compared with the condition be-fore treatment, pain in patients was greatly relieved , and the total pain relief rate was 97.5%,with the NRS score decreased significantly , and KPS score significantly raised , whose differences were statistically signifi-cant （P〈0.05）.The main side effect was hematologic toxicity and constipation , which could be solved af-ter treatment. Conclusion] Oxycodone combined with Docetaxel has satisfactory efficacy for the pa-tients with moderate to severe pain in NSCLC , thus markedly improving the quality of life of the patients .